Monday 20 April 2026
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Conference News
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • US FDA-related legislation in Congress

US FDA-related legislation in Congress

23 March 2009

Mark Senak, a US expert on pharmaceutical-related communications issues, has compiled on his Eye on FDA blog (www.eye_on_fda.com) a round-up of  legislation in the US Congress that concerns the Food and Drug  Administration. In the House of Representatives, Ron Paul (Republican,  Texas) has proposed the Prescription Drug Affordability Act (HR 163),  which would amend the federal tax code to allow retired citizens to make  larger tax deductions for prescription drug expenses, as well as make  imports legal. Rep Paul is the most averse to public spending national  politician in the USA, so his focus is likely to be the reduction of  income tax and Medicare spending.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

Nxera to receive $10 million milestone from AbbVie deal
Pharmaceutical
Nxera to receive $10 million milestone from AbbVie deal
20 April 2026
Biotechnology
Sanofi's Nuvaxovid COVID-19 vaccine bests tolerability of mNEXSPIKE
20 April 2026
Pharmaceutical
Nuvalent data show activity of ROS1 inhibitor after next-gen TKIs
20 April 2026
Biotechnology
The week in pharma: action, reaction and insight – week to April 17, 2026
19 April 2026
Biotechnology
UCB to acquire Neurona Therapeutics to advance epilepsy portfolio
18 April 2026
Biotechnology
Athernal Bio: targeting leukemia’s precursor – before the disease takes hold
17 April 2026
Pharmaceutical
Grifols successfully completes refinancing
17 April 2026


Company Spotlight

Kailera Therapeutics
A clinical-stage biotechnology company developing next-generation injectable and oral therapies for obesity and cardiometabolic disease, with a pipeline anchored in GLP-1-based combinations and small-molecule approaches.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom


  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising
  • Company News Directory


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin
Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze